OncoMed Pharma (OMED) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- U.S. economy adds 29,000 jobs in September
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- BofA's Hartnett sees risk-off mood lasting until dollar peaks
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
March 8, 2017 4:05 PM ESTDemcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017
Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
REDWOOD CITY, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2016. As of December 31, 2016, cash and short-term investments totaled $184.6 million.Â
With eight... More
